Celltrion Healthcare gets positive CHMP opinion for additional Remsima SC indications, the NHS agrees a deal for a new cystic fibrosis drug, Gilead release an open letter on remdesivir pricing, and Cancer Research UK calls on the Scottish government to urgently restart cancer trials.
Interested in Star’s innovative outsourcing and resourcing solutions?
Contact Operations Director, Mark Ward, on 07872 105 540 or email email@example.com.
On the hunt for a new role, or just curious?
Visit our candidate page, submit your CV to firstname.lastname@example.org, or give our offices a ring!
Daniel O’Day, Chairman & Chief Executive Officer of Gilead Sciences has released an open letter on remdesivir pricing for COVID-19.
NHS England has agreed a deal with Vertex for its three-drug cystic fibrosis therapy Kaftrio, just days after the EMA’s human medicines committee recommended approval of the drug.
The positive opinion recommends adding marketing authorization for Remsima SC for use in the treatment of five indications – inflammatory bowel disease (IBD), Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis.
Cancer Research UK is urging Scotland’s government and health service providers to restart existing clinical trials for cancer as quickly as possible, following a 95% drop in new patients entering trials among the pandemic.
Mexico is in talks with the Chinese government and private Chinese laboratories, as well as the University of Oxford and company AstraZeneca about running trials for experimental COVID-19 vaccines, a senior Mexican official said on Monday.
While you’re here…
…and are interested in our content, why not sign up to our newsletter?
It’s just below here.